Invention Grant
- Patent Title: Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
-
Application No.: US16112016Application Date: 2018-08-24
-
Publication No.: US11224653B2Publication Date: 2022-01-18
- Inventor: Parameswaran Nair , Manali Mukherjee
- Applicant: Cephalon, Inc.
- Applicant Address: US PA North Wales
- Assignee: Cephalon, Inc.
- Current Assignee: Cephalon, Inc.
- Current Assignee Address: US PA North Wales
- Agency: BakerHostetler
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K9/00 ; A61P11/06 ; C07K16/24 ; C07K14/54 ; A61K39/00
Abstract:
Disclosed herein are methods of treating severe glucocorticoid-dependent eosinophilic asthma in a subject whose asthma has been inadequately controlled with subcutaneously-administered mepolizumab. Also provided are methods of predicting responsiveness to anti-IL-5 antibody treatment in a subject having severe glucocorticoid-dependent eosinophilic asthma.
Public/Granted literature
- US20190062421A1 TREATMENT STRATEGY FOR NON-RESPONDERS TO 100MG SUBCUTANEOUS MEPOLIZUMAB Public/Granted day:2019-02-28
Information query
